Despite the trial failure, Sarepta will still seek full approval of AMONDYS 45 and VYONDYS 53 in DMD from the FDA.

At the European Society for Medical Oncology (ESMO) 2025 event, held in Berlin, Germany, between 17-21 October, Celcuity ...

AbbVie's Rinvoq will have to come up against Pfizer’s prospective and Incyte’s approved JAK inhibitors in the non-segmental ...

While AstraZeneca's gefurulimab offered significant improvements to MG-ADL scores, it was bested by a variety of ...

In a Phase I trial, biomarkers seem to suggest the potential for a once or twice yearly dosing of Wave’s siRNA for weight ...

Analysts at GlobalData forecast that GCG/GLP-1RA mazdutide will become a blockbuster seller in China for Innovent by 2030.

Pharma Technology Focus is free to read on all devices. Subscribe to Pharma Technology Focus and never miss an issue. Whether you want to increase brand awareness, deliver a complex message or launch ...

The double-blind, randomised, vehicle-controlled study enrolled 241 patients. Credit: TY Lim / Shutterstock.com. Incyte has announced results from the Phase IIIb TRuE-AD4 trial of Opzelura ...

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...

The company’s stock rose significantly after it announced the full Phase I/II data. Image credit: Lightspring / Shutterstock.com. Intensity Therapeutics’ stock has risen nearly 400% after its oncology ...